Effector perturbations can result from a wide range of biological and physical phenomena, including the binding of a small effector molecule, post-translational modifications, protein binding, temperature changes, and pH changes.
The TFs of this superfamily form a homodimer in vivo, and are activated by the binding of specific small effector molecules to their effector binding domains [ 12].
Allosteric modulation of the function of a protein occurs when the regulatory trigger, such as the binding of a small effector or inhibitor molecule, takes place some distance from the protein's active site.
Guanine nucleotide exchange factor (GEF), which is activated by extracellular stimuli, catalyzes the exchange of GDP with GTP with small GTPases, resulting in the binding of small GTPases to effectors.
The structures of RolR and its complex with resorcinol show the unique regulator binding property and distinct structural elements for DNA binding domain to accommodate to small effectors like resorcinol.
Their malfunction is implicated with numerous pathogenic states that range from metabolic disorders to cancer.[ 313– 316] Receptors respond to the binding of effectors such as small molecules, peptide hormones, or protein ligands.
If the binding of the effector is relatively fast (as the binding of most effectors is) the approximation quality is usually high.
Skeletal and cardiac myosin binding small molecule effectors are inhibitors, including blebbistatin and N-benzyl p-toluene sulfonamide (BTS).
The molecular mechanism underlying these defects involves reduction of group 1 metabotropic glutamate receptors levels, which impairs the binding of the small GTPase RhoA to the postsynaptic membrane and the activation of its downstream effectors RockII and profilinIIa.
